CalciMedica is trading at approximately $0.80 (20% down) as investors lock in gains following a sharp two-session rally tied to regulatory optimism.
- The stock surged 13.1% on July 30 and 19.1% on July 31, fueled by positive sentiment regarding FDA trial alignment and progress.
- Today's decline appears to be a technical pullback and profit-taking from recent highs rather than a reaction to new fundamental news or broader market pressure.